Acalisib - CAS 870281-34-8
Catalog number: 870281-34-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C21H16FN7O
Molecular Weight:
401.405
COA:
Inquire
Targets:
PI3K
Description:
Acalisib, also known as GS-9820,  is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. p110beta/delta PI3K inhibitor GS-9820 inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.
Appearance:
Solid powder
Synonyms:
GS-9820; GS9820; GS 9820; CAL-120; CAL 120; CAL120; Acalisib; UNII-OVW60IDW1D.
MSDS:
Inquire
InChIKey:
DOCINCLJNAXZQF-LBPRGKRZSA-N
InChI:
InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1
Canonical SMILES:
CC(C1=NC2=C(C=C(C=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
Current Developer:
Gilead Sciences
1.[Analoghi sintetici dell'ormone di rilascio dell'ormone luteinizzante per il trattamento del carcinoma prostatico localmente avanzato o metastatico: analisi dei costi diretti e indiretti nello scenario italiano].
Fadda V, Maratea D. Recenti Prog Med. 2015 Dec;106(12):634-40. doi: 10.1701/2094.22656.
Riassunto. Introduzione. Gli analoghi sintetici dell'ormone di rilascio dell'ormone luteinizzante (Lh-Rh) sono utilizzati per diverse indicazioni cliniche. I dati di outcome non riportano differenze significative in termini di efficacia tra i diverse analoghi di sintesi Lh-Rh. Materiali e metodi. La ricerca di letteratura è stata eseguita inserendo le seguenti parole chiave nelle biblioteche biomediche online (PubMed) e nei database online delle Agenzie regolatorie (EMA e FDA): "LHRH agonist AND prostatic cancer", "androgen deprivation therapy", "androgen suppression", "buserelin", "leuprorelin", "goserelin", "triptorelin", "degarelix". Nei costi diretti sono stati inclusi i costi relativi alle visite specialistiche di controllo, il costo dell'esame del PSA e il costo del farmaco. Tra i costi indiretti sono stati inclusi le giornate lavorative perse dal paziente. Risultati. Considerando lo schema terapeutico intermittente per tutti i farmaci considerati, il costo di trattamento più basso è attribuibile alla formulazione di Eligard 22,5 mg mentre la spesa più alta si registra con la somministrazione di Firmagon.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


CAS 900515-16-4 AS-252424

AS-252424
(CAS: 900515-16-4)

AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.

CAS 1245537-68-1 BGT226 (NVP-BGT226)

BGT226 (NVP-BGT226)
(CAS: 1245537-68-1)

BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.

CAS 942289-87-4 PI 828

PI 828
(CAS: 942289-87-4)

PI 828 is a cell permeable 4′-amino derivative which inhibits the p110α, p110β, p110δ, and p110γ subunits of PI 3-kinase. PI-828 is a potent inhibitor of phosph...

AS 252424 bispotassium salt

AS 252424 bispotassium salt is the potassium salt form of AS 252424, which is a potent and selective PI3K p110γ inhibitor.

CAS 1236188-16-1 740 Y-P

740 Y-P
(CAS: 1236188-16-1)

740 Y-P is a cell-permeable phosphopeptide activator of PI3K. It binds to the p85 N- and C-terminal SH2 domains of PI3K but not to GST or the N-terminal domain ...

CAS 934529-30-3 XL PI3K/mTOR inhibitor

XL PI3K/mTOR inhibitor
(CAS: 934529-30-3)

An orally bioactive PI3K/mTOR tyrosine kinase inhibitor.

CAS 870281-82-6 CAL-101 (GS-1101)

CAL-101 (GS-1101)
(CAS: 870281-82-6)

Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

CAS 1252594-99-2 ETP-46321

ETP-46321
(CAS: 1252594-99-2)

ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...

Chemical Structure

CAS 870281-34-8 Acalisib

Quick Inquiry

Verification code

Featured Items